Bristol-Myers Squibb Company
Methods for treating patients at risk for costimulation blockade resistant rejection with belatacept

Abstract:

The present invention provides methods utilizing changes in CD4+CD57+ T cells levels for determining the susceptibility of a transplant patient or patient in need thereof to costimulation blockade resistant rejection. These methods are useful for identifying effective drug regimens for the treatment of immune disorders associated with graft transplantation and/or maintenance of a transplant.